Where GLP-1 Patches Fit Into the Future of Treatment
Discover how GLP-1 patches may reshape metabolic health care. Learn how they work and what the future may hold.
Learn how oral semaglutide may be considered for weight loss in non diabetics, including safety, dosing, and the role of licensed providers.
This content is for informational purposes only and does not constitute medical advice. Medications like semaglutide are only prescribed when clinically appropriate and are dispensed through state-licensed pharmacies. Eden is not a pharmacy or healthcare provider.
Oral semaglutide is best known for its role in managing blood sugar in people with type 2 diabetes, but interest has grown in its potential use for weight loss in non diabetics. While most FDA-approved semaglutide products for weight loss are injectable, some patients are curious about whether the oral form may be an option.
In this article, we’ll explain what oral semaglutide is, how it works, what research says about its use in non diabetics, and how licensed healthcare providers determine whether it may be appropriate.
At Eden, we connect people with independent licensed healthcare providers who review each patient’s medical history and goals before making any treatment recommendations. All prescriptions, if written, are filled by state-licensed U.S. pharmacies.
Oral semaglutide contains the same active ingredient as injectable versions, such as Ozempic® and Wegovy®, but it is taken in tablet form. It belongs to the GLP-1 receptor agonist class of medications, which mimic a naturally occurring hormone involved in blood sugar regulation, digestion, and appetite control.
The FDA-approved oral version of semaglutide, known by the brand name Rybelsus®, is indicated for improving blood sugar in adults with type 2 diabetes. However, clinical research has explored its potential role in weight management among non diabetic adults.
Like its injectable counterparts, oral semaglutide activates GLP-1 receptors in the body, leading to effects that may support weight-related goals:
These effects may contribute to reduced calorie intake and better appetite control, though the magnitude of weight change can vary from person to person.
{{primary-cta}}
Some clinical trials have studied oral semaglutide in adults without diabetes who are living with overweight or obesity. Results have shown varying degrees of weight reduction, with higher doses often producing greater effects. In the OASIS 1 trial, participants without diabetes who had overweight or obesity took a higher dose of oral semaglutide than is currently FDA-approved for diabetes treatment. The medication contained the same active ingredient as Rybelsus®, but the studied dose (50 mg) is not an approved strength in the U.S.
For example, studies published in peer-reviewed journals have reported average weight reductions of several percentage points over a number of months. However, oral formulations for weight loss are not yet FDA-approved, meaning use in non diabetics for this purpose would be determined solely by a licensed provider’s clinical judgment.
If you are a non diabetic considering oral semaglutide for weight loss, a licensed healthcare provider will review:
This evaluation ensures that any decision to start treatment is evidence-based and aligned with your health needs.
{{primary-cta}}
While both forms contain the same active ingredient, there are differences:
A provider can help weigh these factors to decide whether oral or injectable semaglutide is more suitable.
Common side effects of oral semaglutide are similar to the injectable version and may include:
Licensed providers may recommend strategies to minimize discomfort, such as gradual dose escalation and dietary adjustments.
{{primary-cta}}
Oral semaglutide for weight loss in non diabetics is an area of growing interest, but it is not an FDA-approved use at this time. Only a licensed healthcare provider can determine if this treatment is appropriate, taking into account your health profile, goals, and safety considerations.
At Eden, we make it easier to connect with independent licensed medical providers who can evaluate your options and, if appropriate, prescribe treatment through a state-licensed pharmacy.
If you are curious about whether oral semaglutide could be part of your weight management plan, start your online evaluation today.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Eden is not a medical provider or a pharmacy. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Medications are filled by independent, state-licensed pharmacies. Eden does not manufacture, own, or dispense any medications. Please consult a licensed healthcare provider before making any medical decisions.
Knop, F. K., Aroda, V. R., Vale, R. D. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 402(10403), 705–719. https://doi.org/10.1016/s0140-6736(23)01185-6
U.S. Food and Drug Administration. (2025). Rybelsus® prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf